171 related articles for article (PubMed ID: 36579085)
1. Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C.
Abdulla M; Al Ghareeb AM; Husain HAHY; Mohammed N; Al Qamish J
World J Clin Cases; 2022 Dec; 10(34):12566-12577. PubMed ID: 36579085
[TBL] [Abstract][Full Text] [Related]
2. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
4. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients.
El Kassas M; El Sheemy R; Alboraie M; El Badry M; Wifi MN; Youssef N; Ezzat S; Tahoon M; Abdelsalam L; Abdelhakam SM; Ali-Eldin Z
Eur Geriatr Med; 2019 Apr; 10(2):295-302. PubMed ID: 34652758
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Zheng YX; Ma SJ; Xiong YH; Fan XG
J Gastroenterol Hepatol; 2020 Sep; 35(9):1477-1487. PubMed ID: 32246857
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia.
Alarfaj SJ; Alzahrani A; Alotaibi A; Almutairi M; Hakami M; Alhomaid N; Alharthi N; Korayem GB; Alghamdi A
Saudi Pharm J; 2022 Oct; 30(10):1448-1453. PubMed ID: 36387341
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China.
Xia H; Lu C; Wang Y; Zaongo SD; Hu Y; Wu Y; Yan Z; Ma P
Front Pharmacol; 2020; 11():710. PubMed ID: 32508646
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
10. Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population.
Saba J; Abou Rached A; Yaghi C; Sharara A; Ammar W
J Infect Dev Ctries; 2018 Feb; 12(2.1):30S. PubMed ID: 31805005
[TBL] [Abstract][Full Text] [Related]
11. Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting.
Gayam V; Khalid M; Mandal AK; Hussain MR; Mukhtar O; Gill A; Garlapati P; Shrestha B; Guss D; Sherigar J; Mansour M; Mohanty S
Gastroenterology Res; 2018 Apr; 11(2):130-137. PubMed ID: 29707080
[TBL] [Abstract][Full Text] [Related]
12. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.
Fedorchenko SV; Martynovych T; Klimenko Z; Yanchenko V; Solianyk I
J Viral Hepat; 2020 May; 27(5):548-551. PubMed ID: 31894886
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
[TBL] [Abstract][Full Text] [Related]
14. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
[TBL] [Abstract][Full Text] [Related]
17. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
[TBL] [Abstract][Full Text] [Related]
20. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
